Clinical trial NCT03148860: Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA
Official title: Impact of Concomitant Methotrexate on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active Psoriasis Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Psoriatic Arthritis
Keywords: Psoriatic Arthritis
Ustekinumab
Methotrexate
DAS28
Lead sponsor: Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Sponsor class: OTHER
Collaborators: name: Janssen-Cilag Ltd.
First posted: 2017-05-11
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomised, placebo-controlled, double-blind, multicenter study
Primary purpose: TREATMENT

Brief summary: Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. Tumor necrosis factor (TNF) -inhibitors) in rheumatoid arthritis (RA), but its role in Psoriatic Arthritis (PsA) remains unclear.

No data from Randomized Clinical Trials (RCTs) are available to address the questions whether add-on of MTX to UST monotherapy, or a withdrawal of continuous MTX therapy in patients with newly initiated Ustekinumab (UST) treatment or simultaneously induction of MTX with UST in naive active PsA-patients will influence outcome measurements.

So, the purpose of the study is to analyse the effects of blinded MTX-co-medication on outcome in patients treated with UST: Non-inferiority at week 24 of UST monotherapy compared to add-on to MTX in patients with active PsA and at least 12 weeks of MTX treatment prior to screening or who are actually not treated with MTX and do not have prior inadequate response to MTX-treatment for PsA will be demonstrated.

Detailed description: Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. TNF-inhibitors) in rheumatoid arthritis (RA), but its role in Psoriatic Arthritis (PsA) remains unclear. Differences in phenotypical manifestations between PsA and RA might influence the impact of co-medication, treatment response and treatment adherence differently.

Independent from this data, the impact of use of MTX in Ustekinumab (UST) treated patients with active PsA remains unclear: No data from Randomized Clinical Trials (RCTs) are available to address the questions whether add-on of MTX to UST monotherapy, or the other way around, a withdrawal of continuous MTX therapy in patients with newly initiated UST treatment or simultaneously induction of MTX with UST in patients will influence outcome.

There is some evidence that MTX may contribute to improved treatment persistence with anti-TNF therapy, particularly when used in combination with infliximab, but there is very little data to support a benefit in effectiveness in patients receiving concomitant MTX.

Additionally, MTX may play a role in immunogenicity: In the PSUMMIT program the patients with concomitant MTX had lower anti-drug-antibody (ADA) rates than those on UST-monotherapy, although there was no effect on efficacy and safety.

Furthermore, methotrexate treatment manifestations such as dactylitis or enthesitis seems to be ineffective.

In this study, the effect of blinded MTX-co-medication on outcome in patients treated with UST will be analysed. Differences on efficacy, safety and treatment adherence will be calculated related to MTX use in four arms of the stratified, randomized placebo-controlled clinical trial which contains a study treatment period of 52 weeks. The primary endpoint, differences in DAS28 in the treatment groups, will be measured at week 24.

Eligibility criteria: Inclusion Criteria:

Patients with active psoriatic arthritis who are naïve to UST will be stratified to either without MTX-therapy or on MTX-treatment (dosage 15mg once weekly) for at least 12 weeks prior to screening.

* Active PsA is defined as TJC ≥4 and SJC ≥4 (68/66 joint count) and DAS28 ≥ 3,2 at screening
* PsA according to CASPAR criteria
* At least age of 18 years
* Presence of chest x-ray without signs of active or latent infection (esp. for tuberculosis) within the last 3 months
* Permitted pre-treatment with up to three biologic-agents, whereupon only one biologic agent must be withdrawn due to inadequate response.
* For MTX-naive patients: Previous use of NSAID
* Written informed consent obtained prior to the initiation of any protocol-required procedures
* Compliance to study procedures and study protocol Inclusion criteria related to MTX
* For the group on MTX: Patients must have stable MTX dosages of at least 15mg once weekly for at least 12 weeks prior to screening and stable MTX dosages of at 15mg once weekly for at least 4 weeks prior to screening
* Compliance of intake of MTX must be documented by treating physician
* For the group without MTX therapy: patients must be eligible for MTX treatment (according to SmPC) and have not failed prior MTX treatment for the treatment of PsA

Exclusion Criteria:

Exclusion criteria related to Investigational medicinal product (IMP):

* Previous use of UST or any other anti-IL23 agent
* according to SmPC

Exclusion criteria for the group without MTX:

- Inadequate Response to prior MTX-treatment for Psoriatic Arthritis

Exclusion criteria related to general health:

* previous B-cell depleting therapy
* Patients with other chronic inflammatory articular disease or systemic autoimmune disease with musculoskeletal symptoms
* Patients with active Tb
* Patients with latent Tb, measured by Interferon gamma release assay, that are not pre-treated for at least 1 months and planned to be treated 9 months in total with INH once a day according to local guidelines
* Any active infection, a history of recurrent clinically significant infection, a history of recurrent bacterial infections with encapsulated organisms
* Primary or secondary immunodeficiency
* History of cancer with curative treatment not longer than 5 years ago except basal-cell carcinoma of the skin that had been excised
* Evidence of significant uncontrolled concomitant diseases or serious and/or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome
* History of a severe psychological illness or condition
* Known hypersensitivity to any component of the product
* Women lactating, pregnant, nursing or of childbearing potential with a positive pregnancy test
* Males or females of reproductive potential not willing to use effective contraception (e.g. contraceptive pill, IUD, physical barrier)
* Alcohol, drug or chemical abuse Exclusion criteria related to prior treatments
* Previous DMARD therapy other than MTX at least for the last 28 days prior screening due to washout time of different DMARD therapies (including Leflunomide etc.)
* Previous immunosuppressive biologic therapy at least for the last
* 4 weeks prior to screening for Enbrel® (etanercept) - with a terminal half-life of 102 ± 30 hours (s.c. route)
* 10 weeks prior to screening for Humira® (adalimumab) - with a terminal half-life of 10-20 days (average 2 weeks) (s.c. route)
* 10 weeks prior to screening for Simponi® (golimumab) - with a terminal half-life of 11-14 days
* 10 weeks prior to screening for Cimzia® (certolizumab) - with a terminal half-life of approx. 14 days
* 8 weeks prior to screening for Remicade® (infliximab) - with a terminal half-life of 8.0-9.5 days (i.v. infusion)
* 60 days prior to screening due to washout time of other immunosuppressive biologic therapies
* current participation in another interventional clinical trial

Exclusion criteria related to laboratory:

* Haemoglobin \< 8.5 g / dl
* Neutrophil counts \< 1.500 / μl
* Platelet count \< 75.000 / μl
* Lower than 1 x 1000 / μl lymphopenia for more than three months prior to inclusion.
* Serum creatinine \> 1.4 mg / dl for women or 1.6 mg / dl for men
* AST or ALT \> 2.5 time upper limit of norm

Exclusion criteria related to formal aspects:

- Underage or incapable patients

Primary outcomes:
measure: Assessment of mean values of DAS28 at week 24
timeFrame: week 24
Secondary outcomes:
measure: Assessment of mean DAS28 at week 52
timeFrame: week 52
measure: Assessment of DAS28
timeFrame: week 4
measure: Assessment of DAS28
timeFrame: week 16
measure: Assessment of DAS28
timeFrame: week 24
measure: Assessment of DAS28
timeFrame: week 40
measure: Assessment of DAS28
timeFrame: week 52
measure: change in DAS28
timeFrame: baseline to week 4
measure: change in DAS28
timeFrame: baseline to week 16
measure: change in DAS28
timeFrame: baseline to week 24
measure: change in DAS28
timeFrame: baseline to week 40
measure: change in DAS28
timeFrame: baseline to week 52
measure: DAS28-ESR remission
timeFrame: week 4
measure: DAS28-ESR remission
timeFrame: week 16
measure: DAS28-ESR remission
timeFrame: week 24
measure: DAS28-ESR remission
timeFrame: week 40
measure: DAS28-ESR remission
timeFrame: week 52
measure: Assessment of Tender joint count/Swollen joint count (TJC/SJC) (68/66)
timeFrame: week 4
measure: Assessment of TJC/SJC (68/66)
timeFrame: week 16
measure: Assessment of TJC/SJC (68/66)
timeFrame: week 24
measure: Assessment of TJC/SJC (68/66)
timeFrame: week 40
measure: Assessment of TJC/SJC (68/66)
timeFrame: week 52
measure: ACR (20/50/70) response
timeFrame: week 4
measure: ACR (20/50/70) response
timeFrame: week 16
measure: ACR (20/50/70) response
timeFrame: week 24
measure: ACR (20/50/70) response
timeFrame: week 40
measure: ACR (20/50/70) response
timeFrame: week 52
measure: Change in ACR core set
timeFrame: baseline to week 4
measure: Change in ACR core set
timeFrame: baseline to week 16
measure: Change in ACR core set
timeFrame: baseline to week 24
measure: Change in ACR core set
timeFrame: baseline to week 40
measure: Change in ACR core set
timeFrame: baseline to week 52
measure: Assessment of PASI
timeFrame: week 4
measure: Assessment of BASDAI
timeFrame: week 4
measure: Assessment of BSA
timeFrame: week 4
measure: Assessment of BASDAI
timeFrame: week 16
measure: Assessment of PASI
timeFrame: week 16
measure: Assessment of BSA
timeFrame: week 16
measure: Assessment of BASDAI
timeFrame: week 24
measure: Assessment of PASI
timeFrame: week 24
measure: Assessment of BSA
timeFrame: week 24
measure: Assessment of PASI
timeFrame: week 40
measure: Assessment of BSA
timeFrame: week 40
measure: Assessment of BASDAI
timeFrame: week 40
measure: Assessment of PASI
timeFrame: week 52
measure: Assessment of BSA
timeFrame: week 52
measure: Assessment of BASDAI
timeFrame: week 52
measure: Treatment adherence measured by patient diary
timeFrame: through treatment period; normally 52 weeks
measure: Compliance measured by questionnaire CQR5
timeFrame: through treatment period; normally 52 weeks
measure: Quality of life measured by HAQ
timeFrame: week 4
measure: Quality of life measured by EQ5D
timeFrame: week 4
measure: Quality of life measured by DLQI
timeFrame: week 4
measure: Quality of life measured by EQ5D
timeFrame: week 16
measure: Quality of life measured by HAQ
timeFrame: week 16
measure: Quality of life measured by DLQI
timeFrame: week 16
measure: Quality of life measured by DLQI
timeFrame: week 24
measure: Quality of life measured by EQ5D
timeFrame: week 24
measure: Quality of life measured by HAQ,
timeFrame: week 24
measure: Quality of life measured by HAQ
timeFrame: week 40
measure: Quality of life measured by EQ5D
timeFrame: week 40
measure: Quality of life measured by DLQI
timeFrame: week 40
measure: Quality of life measured by HAQ
timeFrame: week 52
measure: Quality of life measured by EQ5D
timeFrame: week 52
measure: Quality of life measured by DLQI
timeFrame: week 52
measure: Assessment of Change in Dactylitis
timeFrame: week 4, 16, 24, 40 and week 52
measure: Assessment of Change in Enthesitis (LEI)
timeFrame: week 4, 16, 24, 40 and week 52
measure: Assessment of mtNAPSI
timeFrame: week 4, 16, 24, 40 and week 52
measure: Ultrasound (US) assessment of joints and enthesis according to PASON22
timeFrame: Week 4, 24 and week 52
measure: Frequency and seriousness of adverse events as reported and documented in Case report form
timeFrame: each study visit (week 0 to week 52)
Other outcomes:
Locations:
city: Frankfurt am Main
country: Germany
facility: CIRI
state: Hessia
Study officials:
affiliation: Fraunhofer IME
name: Frank Behrens, MD
role: PRINCIPAL_INVESTIGATOR
References: